DUBLIN--(BUSINESS WIRE)--The "Biosimilar Monoclonal Antibodies Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2023" report has been added to ResearchAndMarkets.com's offering.
The report predicts the global biosimilar monoclonal antibodies market to grow with a CAGR of 42.8% over the forecast period of 2017-2023
The report on biosimilar monoclonal antibodies market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global biosimilar monoclonal antibodies market over the period of 2015 to 2023. Moreover, the report is collective presentation of primary and secondary research findings.
Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global biosimilar monoclonal antibodies market over the period of 2015 to 2023. Further, the Growth Matrix given in the report brings an insight on the investment areas that existing or new market players can consider.
The global biosimilar monoclonal antibodies market is segmented on the basis of drug class and application.
Global Biosimilar Monoclonal Antibodies Market by Drug Class
Global Biosimilar Monoclonal Antibodies Market by Application
- Chronic And Autoimmune Diseases
- Growth Hormone Deficiency
- Infectious Diseases
Global Biosimilar Monoclonal Antibodies Market by Region
- North America
- Asia Pacific
- Latin America
- Rest of the World
- Pfizer, Inc.
- Novartis AG
- Reliance Life Sciences
- Allergan plc.
- Coherus BioSciences
- Dr. Reddy's Laboratories Ltd.
- Boehringer Ingelheim GmbH
- BioXpress Therapeutics SA
- Intas Pharmaceuticals Limited
- Genor BioPharma Co. Ltd
- Celltrion, Inc.
For more information about this report visit https://www.researchandmarkets.com/research/b8nlj3/global_biosimilar?w=4